Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

NCT05007860 · clinicaltrials.gov ↗

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.

Sponsor

Massachusetts General Hospital